Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Public Equities L.P. Invus bought 145,680 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was acquired at an average cost of $9.74 per share, for a total transaction of $1,418,923.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Public Equities L.P. Invus also recently made the following trade(s):
- On Tuesday, November 14th, Public Equities L.P. Invus bought 575,946 shares of Lexicon Pharmaceuticals stock. The stock was acquired at an average cost of $9.64 per share, for a total transaction of $5,552,119.44.
Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) traded down $0.08 during trading on Tuesday, reaching $9.73. 888,000 shares of the company traded hands, compared to its average volume of 804,741. Lexicon Pharmaceuticals, Inc. has a 12-month low of $8.07 and a 12-month high of $18.00. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The firm had revenue of $26.94 million during the quarter, compared to the consensus estimate of $27.97 million. During the same quarter last year, the firm earned ($0.35) EPS. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. sell-side analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.45 EPS for the current year.
A number of institutional investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in Lexicon Pharmaceuticals by 0.9% in the 2nd quarter. FMR LLC now owns 15,785,280 shares of the biopharmaceutical company’s stock valued at $259,668,000 after purchasing an additional 137,421 shares during the last quarter. Vanguard Group Inc. boosted its position in Lexicon Pharmaceuticals by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 4,168,301 shares of the biopharmaceutical company’s stock valued at $59,773,000 after buying an additional 585,222 shares during the period. USS Investment Management Ltd purchased a new position in Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $57,705,000. Eagle Asset Management Inc. boosted its position in Lexicon Pharmaceuticals by 0.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 2,861,065 shares of the biopharmaceutical company’s stock valued at $47,064,000 after buying an additional 8,756 shares during the period. Finally, State Street Corp boosted its position in Lexicon Pharmaceuticals by 19.9% in the 2nd quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock valued at $32,363,000 after buying an additional 326,088 shares during the period.
A number of research analysts have weighed in on LXRX shares. Needham & Company LLC reissued a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. Wedbush restated an “outperform” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, October 5th. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Finally, Cowen and Company restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus target price of $28.75.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.